UY32354A - Composición de micropartículas biocompatibles de ácido algínico para la liberación - Google Patents

Composición de micropartículas biocompatibles de ácido algínico para la liberación

Info

Publication number
UY32354A
UY32354A UY0001032354A UY32354A UY32354A UY 32354 A UY32354 A UY 32354A UY 0001032354 A UY0001032354 A UY 0001032354A UY 32354 A UY32354 A UY 32354A UY 32354 A UY32354 A UY 32354A
Authority
UY
Uruguay
Prior art keywords
microparticles
composition
biocompatible
alginic acid
release
Prior art date
Application number
UY0001032354A
Other languages
English (en)
Inventor
Salvador Grancha Gamon
Anna Nardi Ricart
Josep Maria Sune Negre
Josep Ramon Tico Grau
Montserrat Minarro Carmona
Original Assignee
Grifols Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40793335&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32354(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grifols Sa filed Critical Grifols Sa
Publication of UY32354A publication Critical patent/UY32354A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a: -composición de micropartículas biocompatibles de ácido algínico o sus sales y un principio activo para la liberación controlada de principios activos por vía intravenosa. -particularmente a micropartículas para la encapsulación de un principio activo que va a ser administrado por vía intravenosa a un paciente que lo necesite. Dichas micropartículas que tienen una combinación de tamaño adecuada para lograr un incremento de la vida media o permanencia del principio activo en sangre, con una baja captación hepática y un rápido aclaramiento celular cuando son administradas por vía intravenosa.
UY0001032354A 2008-12-23 2009-12-22 Composición de micropartículas biocompatibles de ácido algínico para la liberación UY32354A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200803671A ES2319158B1 (es) 2008-12-23 2008-12-23 Composicion de microparticulas biocompatibles de acido alginico para la liberacion controlada de principios activos por via intravenosa.

Publications (1)

Publication Number Publication Date
UY32354A true UY32354A (es) 2010-07-30

Family

ID=40793335

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032354A UY32354A (es) 2008-12-23 2009-12-22 Composición de micropartículas biocompatibles de ácido algínico para la liberación

Country Status (17)

Country Link
US (1) US7931916B2 (es)
EP (1) EP2201940B1 (es)
JP (2) JP5297994B2 (es)
CN (1) CN101757631B (es)
AR (1) AR074820A1 (es)
AU (1) AU2009248454B2 (es)
BR (1) BRPI0906284A2 (es)
CA (1) CA2688047C (es)
CL (1) CL2009002204A1 (es)
ES (2) ES2319158B1 (es)
HK (1) HK1141451A1 (es)
HU (1) HUE028485T2 (es)
MX (1) MX2009014178A (es)
NZ (1) NZ582166A (es)
PL (1) PL2201940T3 (es)
RU (1) RU2476235C2 (es)
UY (1) UY32354A (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102429862B (zh) * 2011-11-29 2013-05-01 江苏德达医药科技有限公司 一种聚维酮碘眼用缓释滴眼液
RU2519158C1 (ru) * 2013-03-28 2014-06-10 Федеральное государственное бюджетное учреждение "Саратовский научно-исследовательский институт травматологии и ортопедии" Министерства здравоохранения Российской Федерации (ФГБУ "СарНИИТО" Минздрава России) Биодеградируемое раневое покрытие и способ получения биодеградируемого раневого покрытия
CN104888226A (zh) * 2014-03-06 2015-09-09 中国科学院大连化学物理研究所 一种蛋白质和/或多肽类物质的制剂
WO2016198351A1 (en) * 2015-06-10 2016-12-15 Evonik Röhm Gmbh Process for preparing a powder comprising a human coagulation factor protein and a lactic acid polymer
EP3411022B1 (en) 2016-02-01 2021-09-15 Emory University Particles for targeted delivery and uses in managing bleeding or blood clotting
US20190343871A1 (en) * 2017-01-31 2019-11-14 Georgia Tech Research Corporation Compositions and Methods for Inhibiting Shear Induced Platelet Accumulation

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518046A (en) 1982-06-21 1985-05-21 Deere & Company Multiple implement hitch and transport
WO1991009119A1 (en) * 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5334640A (en) 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
US5417982A (en) 1994-02-17 1995-05-23 Modi; Pankaj Controlled release of drugs or hormones in biodegradable polymer microspheres
RU2071765C1 (ru) * 1994-07-14 1997-01-20 Российский научно-исследовательский институт гематологии и трансфузиологии Способ получения липосом
US6565842B1 (en) * 1995-06-07 2003-05-20 American Bioscience, Inc. Crosslinkable polypeptide compositions
JP3765338B2 (ja) * 1995-12-15 2006-04-12 武田薬品工業株式会社 注射用徐放性製剤の製造法
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
JPH11130698A (ja) 1997-10-31 1999-05-18 Freunt Ind Co Ltd アルギン酸多価金属塩球状微粒子集合体、該球状微粒子集合体に難溶性薬剤を担持した放出制御製剤及びそれらの製造方法
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
EP1498100A4 (en) * 2002-03-29 2008-04-02 Shiseido Co Ltd COMPOSITE POWDER AND THIS INCLUDING COSMETICS
AU2003221579A1 (en) 2002-04-30 2003-11-17 Canadian Blood Services Encapsulated cells to elicit immune response
WO2006028996A2 (en) 2004-09-03 2006-03-16 Trustees Of Tufts College Emulsan-alginate microspheres and methods of use thereof
CN101188996B (zh) * 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
RU2429864C2 (ru) 2005-10-21 2011-09-27 Ливинг Селл Продактс Пти Лимитед Система инкапсуляции
DE102005051366A1 (de) * 2005-10-25 2007-04-26 Degussa Gmbh Drug Delivery Systeme
US8231907B2 (en) 2006-03-21 2012-07-31 Morehouse School Of Medicine Nanoparticles for delivery of active agents
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
WO2008022146A2 (en) 2006-08-14 2008-02-21 Wayne State University Polymer-surfactant nanoparticles for sustained release of compounds
EP1958622A1 (en) * 2006-11-07 2008-08-20 Royal College of Surgeons in Ireland Method of producing microcapsules
US9114127B2 (en) 2007-05-15 2015-08-25 Richard C. K. Yen Biologic devices for hemostasis
DE202008009270U1 (de) 2008-07-10 2009-11-12 Steelcase Werndl Ag Wandförmiges Standmöbel
EP2159523B1 (en) 2008-08-29 2018-08-01 Electrolux Home Products Corporation N.V. Refrigeration equipment and console system for use therein

Also Published As

Publication number Publication date
HUE028485T2 (en) 2016-12-28
EP2201940A1 (en) 2010-06-30
ES2563632T3 (es) 2016-03-15
JP2010150257A (ja) 2010-07-08
MX2009014178A (es) 2010-06-30
AU2009248454B2 (en) 2011-07-28
CN101757631A (zh) 2010-06-30
PL2201940T3 (pl) 2016-06-30
CA2688047A1 (en) 2010-06-23
EP2201940B1 (en) 2016-02-24
AR074820A1 (es) 2011-02-16
JP5698296B2 (ja) 2015-04-08
CN101757631B (zh) 2013-02-27
RU2476235C2 (ru) 2013-02-27
CL2009002204A1 (es) 2010-05-07
ES2319158B1 (es) 2010-01-26
BRPI0906284A2 (pt) 2013-07-30
NZ582166A (en) 2011-06-30
US20100159017A1 (en) 2010-06-24
AU2009248454A1 (en) 2010-07-08
JP2013136636A (ja) 2013-07-11
JP5297994B2 (ja) 2013-09-25
ES2319158A1 (es) 2009-05-04
US7931916B2 (en) 2011-04-26
RU2009147838A (ru) 2011-06-27
HK1141451A1 (en) 2010-11-12
CA2688047C (en) 2012-08-21

Similar Documents

Publication Publication Date Title
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
UY32354A (es) Composición de micropartículas biocompatibles de ácido algínico para la liberación
CO6670567A2 (es) Métodos de tratamiento contra el cáncer pancreático
CY1123334T1 (el) Σκευασματα φιναστεριδης για αποδεσμευση φαρμακου στα μαλλια και στο τριχωτο της κεφαλης
GT201400285A (es) Formulacion de anticuerpos
DOP2015000234A (es) COMPOSICIONES DE ARNi CONTRA EL COMPONENTE C5 DEL COMPLEMENTO Y METODOS PARA SU USO.
BR112015008666A2 (pt) fita para a liberação de um ativo para tratamento bucal e métodos para a aplicação de ativos para tratamento bucal
UY33700A (es) ?combinaciones farmacéuticas para el tratamiento de trastornos metabólicos?.
PE20211069A1 (es) Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CL2012003573A1 (es) Combinaciones que comprenden un derivado de antranilamida y otro principio activo con propiedades insecticidas y acaricidas; composiciones agroquimicas que contienen; uso de dicha combinacion; procedimiento para combatir parasitos animales; y procedimiento para la preparacion de dicha composicion agroquimica.
GT201200276A (es) Combinaciones de compuestos activos
GT201300235A (es) Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas
DOP2009000178A (es) Formulaciones para el tratamiento del cancer
BR112014031914A2 (pt) cápsula de estradiol solúvel para inserção vaginal
AR080483A1 (es) Metodo para estabilizar dispersiones acuosas de compuestas bioactivos en agua
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
AR056500A1 (es) Metodo para preparar una composicion medica
GT200900284A (es) Dosis intravenosa y oral de un inhibidor p2y12 de accion directa y reversible.-
CL2017001026A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención.
TR200806298A2 (tr) Farmasötik formülasyon
ECSP099439A (es) Composición de liberación sostenida y métodos para producirla
CO7151496A2 (es) Agentes terapeúticos para administración subcutánea optimizados
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
AR102778A1 (es) Composición farmacéutica, su preparación y sus usos

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20201223